First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity

Glioblastoma multiforme (GBM) patients have a poor prognosis. After tumor recurrence statistics suggest an imminent death within 1–4.5 months. Supportive preclinical data, from a rat model, provided the rational for a prototype clinical vaccine preparation, named Gliovac (or ERC 1671) composed of au...

Descripción completa

Detalles Bibliográficos
Autores principales: Schijns, Virgil E.J.C., Pretto, Chrystel, Devillers, Laurent, Pierre, Denis, Hofman, Florence M., Chen, Thomas C., Mespouille, Pascal, Hantos, Peter, Glorieux, Philippe, Bota, Daniela A., Stathopoulos, Apostolos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494870/
https://www.ncbi.nlm.nih.gov/pubmed/25865468
http://dx.doi.org/10.1016/j.vaccine.2015.03.095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494870/
https://www.ncbi.nlm.nih.gov/pubmed/25865468
http://dx.doi.org/10.1016/j.vaccine.2015.03.095

Ejemplares similares